JY
LPCN icon

Jeff Yass’s Lipocine LPCN Stock Holding History

Jeff Yass’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-935
Closed -$7K – 13131
2022
Q3 		$7K Sell
935
-524
-36% -$5.85K ﹤0.01% 12838
2022
Q2 		$20K Sell
1,459
-676
-32% -$10.5K ﹤0.01% 12365
2022
Q1 		$50K Sell
2,135
-4,147
-66% -$86.8K ﹤0.01% 12315
2021
Q4 		$106K Buy
6,282
+3,953
+170% +$73.4K ﹤0.01% 12107
2021
Q3 		$43K Sell
2,329
-1,706
-42% -$37.6K ﹤0.01% 12397
2021
Q2 		$96K Sell
4,035
-13,747
-77% -$323K ﹤0.01% 12113
2021
Q1 		$456K Buy
17,782
+16,935
+1,999% +$489K ﹤0.01% 9698
2020
Q4 		$20K Sell
847
-4,924
-85% -$119K ﹤0.01% 10882
2020
Q3 		$138K Buy
+5,771
New +$153K ﹤0.01% 9739
2018
Q1 		– Sell
-788
Closed -$46K – 9802
2017
Q4 		$46K Buy
+788
New +$49K ﹤0.01% 8929
2016
Q4 		– Sell
-1,759
Closed -$133K – 9889
2016
Q3 		$133K Sell
1,759
-6,759
-79% -$419K ﹤0.01% 7826
2016
Q2 		$440K Buy
8,518
+7,689
+928% +$1.19M ﹤0.01% 6342
2016
Q1 		$143K Buy
+829
New +$141K ﹤0.01% 8242

Other funds holding LPCN

SCM
Squadron Capital Management Westmont, Illinois $322M AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jeff Yass's LPCN Position: Q2 2026 in Review

Jeff Yass increased its Lipocine (LPCN) stake by 1.9% in Q2 2026, buying an estimated $1.13K and bringing the position to 25,376 shares worth $65K. The position accounts for ﹤0.01% of the portfolio, ranked #12733.

Jeff Yass first reported a position in LPCN in Q4 2015 and has held it in 32 quarters since. The position peaked at $700K in Q1 2016. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

  • Jeff Yass held 25,376 shares of Lipocine worth $65K as of Q2 2026.
  • Jeff Yass bought 468 Lipocine shares in Q2 2026, an estimated $1.13K.
  • Lipocine made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12733 holding.
  • Jeff Yass first reported a position in Lipocine in Q4 2015 and has held it in 32 quarters since.
  • Jeff Yass's Lipocine position peaked at $700K in Q1 2016.
  • 36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.